ECCO 2018

2018-02-14 - 2018-02-17
Vienna, Austria

SABCS 2017

2017-12-05 - 2017-12-09
San Antonio, United States

ESMO 2017

2017-09-08 - 2017-09-12
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASCO 2017

2017-06-02 - 2017-06-06
Chicago, United States

SABCS 2016

2016-12-06 - 2016-12-10
San Antonio, United States

ESMO 2016

2016-10-07 - 2016-10-11
Copenhagen, Denmark

ASCO 2016

2016-06-03 - 2016-06-07
Chicago, United States

ELCC 2016

2016-04-13 - 2016-04-16
Geneva, Switzerland
Search in Scientific Content:
Date
Filters:
Results fr
5:010

Results from the phase 3 PARADIGM trial

Presenter: Yoshino Takayuki
ASCO 2022
Pembrolizu
6:32

Pembrolizumab in CRC: What did we learn from the KEYNOTE-177 and the KEYNOTE-651 trials?

Presenter: Richard D. Kim
ASCO 2022
Early brea
6:31

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Presenter: Sibylle Loibl
Specialty: Breast Cancer
ESMO Breast Cancer 2022
Novelties
6:04

Novelties at the International Summit of Lung Cancer in Rome

Presenter: Federico Cappuzzo
Specialty: Lung Cancer
International Summit of Lung Cancer
Highlights
10:33

Highlights of the San Antonio Breast Cancer Symposium 2021

Presenter: Virginia G. Kaklamani
Specialty: Breast Cancer
SABCS 2021
Correlativ
4:24

Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies

Presenter: Lisa A. Carey
Specialty: Breast Cancer
SABCS 2021
Final resu
5:20

Final results of KEYNOTE-355

Presenter: Javier Cortes
Specialty: Breast Cancer
SABCS 2021
PALLAS tri
8:41

PALLAS trial: Adjuvant palbociclib in HR+/HER2- early breast cancer

Presenter: Michael Gnant
Specialty: Breast Cancer
SABCS 2021
The DESTIN
5:07

The DESTINY-Breast03 trial

Presenter: Sara Hurvitz
Specialty: Breast Cancer
SABCS 2021
Spotlight
16:53

Spotlight on the emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC)

Presenter: Peter Galle
ESMO 2021
The MONALE
8:37

The MONALEESA-2 trial

Presenter: Gabriel N. Hortobagyi
ESMO 2021
Should Cur
16:32

Should Cure Be A Reasonable Goal in aRCC?

Presenter: David F. McDermott
ESMO 2021
Is Unresec
6:32

Is Unresectable Malignant Pleural Mesothelioma a New Frontier for I-O?

Presenter: Alessandra Curioni-Fontecedro
ESMO 2021
The Keynot
7:05

The Keynote 716 trial

Presenter: Jason J. Luke
ESMO 2021
Navigating
5:56

Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB

Presenter: Judy King
ESMO 2021
Metastases
7:04

Metastases-free survival results from STAMPEDE trial

Presenter: Gerhardt Attard
ESMO 2021
Effects of
11:15

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Presenter: Richard Gray
Specialty: Breast Cancer
Alpelisib
14:48

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Presenter: Dejan Juric
Specialty: Breast Cancer
Lifestyle
8:40

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Presenter: Wolfgang Janni
Specialty: Breast Cancer
Choice of
8:39

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Presenter: Laura Dominici
Specialty: Breast Cancer
Circulatin
10:32

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Presenter: Francois-Clement Bidard
Specialty: Breast Cancer
Axillary R
9:45

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Presenter: Emiel J. T. Rutgers
Specialty: Breast Cancer
Accelerate
6:19

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Presenter: Fank Vicini
Specialty: Breast Cancer
A randomiz
10:32

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

Presenter: Andrea De Censi
Specialty: Breast Cancer
PALLET: A
12:51

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Presenter: Mitchell Dowsett
Specialty: Breast Cancer
Phase III
9:33

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Presenter: Charles E. Geyer, Jr
Specialty: Breast Cancer
Adjuvant C
8:05

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Presenter: Miguel Martín
Specialty: Breast Cancer
Adjuvant C
7:33

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Presenter: Laura Spring
Specialty: Breast Cancer
Delaying A
5:48

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Presenter: Zaida Morante
Specialty: Breast Cancer
Low-Dose T
9:12

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Presenter: Andrea De Censi
Specialty: Breast Cancer
Increasing
11:01

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Presenter: Richard Gray
Specialty: Breast Cancer
Phase Ib/I
8:36

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)

Presenter: Sherene Loi
Specialty: Breast Cancer
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
First-line
7:41

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato